Platelet inhibition in cardiovascular disease management: Aspirin and beyond

Journal of Thrombosis and Thrombolysis

Volumn 5, Issue SUPPL. 1, 1998, Pages

  Harrington, Robert A ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Anticoagulation; Antiplatelet; Clopidogrel; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR; HEPARIN; STREPTOKINASE; TICLOPIDINE;

ANGIOPLASTY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; STENT; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0031890799     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. American Heart Association. Heart and Stroke Facts. Dallas, TX: American Heart Association, 1993. See also http://www.amhrt.org/hs96/cvds.html.
2. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. Rockville, MD: Agency for Health Care Policy and Research, 1994:1-154.
3. Myler RK, Stertzer SH. Coronary and peripheral angioplasty: Historic perspective. In: Topol EJ, ed. Textbook of Interventional Cardiology, 2nd ed. Philadelphia: W.B. Saunders, 1994:171-185.
4. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med 1992;326:10-16.
5. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-225.
6. King SB, 3rd, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994;331:1044-1050.
7. CABRI Trial Paticipants. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). Lancet 1995;346:1179-1184.
8. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-250, 310-318.
9. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
10. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1996;308:81-106.
11. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135.
12. ISIS-2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
13. Wallentin LC and Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 1991;18:1617-1626.
14. Cairns JA, Gent M, Singer J. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985;313:1369-1375.
15. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-1111.
16. Lewis HD Jr. Unstable angina: Status of aspirin and other forms of therapy. Circulation 1985;72(Suppl. V):V155-V160.
17. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993;87:659-675.
18. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1997;334:1084-1089.
19. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-222.
20. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
21. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-2380.
22. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
23. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
24. The IMPACT II Investigators. Effects of integrelin, a platelet glycoprotein IIb/IIIa inhibitor, in preventing ischemic complications of percutaneous coronary intervention.Lancet 1997;349:1422-28.
25. Ferguson JJ. Meeting highlights: American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24-27,1996. Circulation 1996;94:1-5.
26. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
27. Lincoff AM, Califf RM, Anderson KM, et al. for the EPIC Investigators. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997;30:149-156.
28. EPIC three year results. European Society of Cardiology Meeting, Birmingham, England, August 1996.
29. Alexander KA, Bareness GW, Miller JM, Tung CY. AHJ at the ACC. Am Heart J 1997;134, in press.
30. Cannon CP, Novotny WF, McCabe CH, et al. Evaluation of the oral glycoprotein IIb/IIIa antagonist Ro 48-3657 in patients post acute coronary syndromes: Primary results of the TIMI 12 trial (abstr) Circulation 1996;94(Suppl. I):I552.